Trial Profile

Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Ipilimumab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms Rad-IO

Most Recent Events

10 Jan 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
10 Jan 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2024.
10 Jan 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com